<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869593</url>
  </required_header>
  <id_info>
    <org_study_id>18-AOI-08</org_study_id>
    <nct_id>NCT03869593</nct_id>
  </id_info>
  <brief_title>Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria</brief_title>
  <acronym>NLRP3-Bact</acronym>
  <official_title>Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our previous studies delineate a novel pathway of immune activation in animals that the
      investigators have named Anti-Virulence Immunity (AVI). Using a mice model of bacteremia, the
      investigators have demonstrated that Escherichia coli Cytotoxic Necrotizing Factor 1 (CNF1)
      activity is sensed by the immune system. This immune sensing results in a rapid bacterial
      clearing during bacteremia triggered by uropathogenic E. coli-expressing CNF1. The
      investigators already confirmed the involvement of one inflammasome using macrophages
      isolated from Knock-out mice. The investigators have recently determined the conservation in
      human monocytes of the interleukin -1beta maturation triggered by CNF1 and observed the
      heterogeneous capacity of monocytes to respond to the CNF1 treatment depending on the donors.
      Here, to determine the importance in natura of AVI the investigators will analyze the blood
      content of patients presenting E. coli and S. aureus bacteremia. The DNA of monocytes
      isolated from patients will be extracted and various genes implicated in the activity of
      various inflammasomes will be sequenced to identify mutations that could explain the
      susceptibility to bacteremia or a specific clinical presentation, i.e. requirement of a
      management in ICU because of organ failure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establish an association between mutations in some inflammasomes and occurrence of E. coli associated with sepsis.</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish an association between mutations in some inflammasomes and occurrence of S. aureus bacteremia associated with sepsis.</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Escherichia Coli Infections</condition>
  <condition>Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>Patients presenting E. coli and S. aureus bacteremia</arm_group_label>
    <description>Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Sample analysis</intervention_name>
    <description>Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia</description>
    <arm_group_label>Patients presenting E. coli and S. aureus bacteremia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      2 samples of blood will be collected during a routine blood test. A sample will allow the
      analysis of the study, the second will join a biobank.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with S. aureus or E. coli bacteremia defined by at least one positive blood culture
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with S. aureus or E. coli bacteriostatic bacteremia defined by at least one
             positive blood culture bottle

          -  Patient requiring a blood test as part of his bacteremia

          -  not subject to a judicial protection measure

          -  Signature of the non-opposition of consent (for minor patients signed by one of the
             parents or the representative of the parental authority)

          -  Affiliation to social security

        Exclusion Criteria:

          -  Immunocompromised patient defined by:

               -  current immunosuppressive therapies: corticosteroids, chemotherapy, biotherapy

               -  solid organ transplant patient or hematopoietic stem cell transplant

               -  chemotherapy-induced neutropenia

               -  Congenital immune deficiency

          -  bacteremia related to a peripheral or central catheter

          -  Urinary obstruction not lifted within the first 24 hours of management

          -  Intra-abdominal infection collected undrained in the first 24 hours of management

          -  primary infectious focus represented by mechanically ventilated pneumonia

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan COURJON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johan COURJON, MD</last_name>
    <phone>04 92 03 54 52</phone>
    <email>courjon.j@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johan Johan, Johan</last_name>
    <phone>04 92 03 54 52</phone>
    <email>courjon.j@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHG d'Antibes</name>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe DE SWART, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Pierre Nouveau</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-Marie BERTRAND, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lenval</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hervé HAAS, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Lee CC, Chen SY, Chang IJ, Chen SC, Wu SC. Comparison of clinical manifestations and outcome of community-acquired bloodstream infections among the oldest old, elderly, and adult patients. Medicine (Baltimore). 2007 May;86(3):138-44. Erratum in: Medicine (Baltimore). 2013 Jul;92(4):216.</citation>
    <PMID>17505253</PMID>
  </reference>
  <reference>
    <citation>Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997 Apr;24(4):584-602.</citation>
    <PMID>9145732</PMID>
  </reference>
  <reference>
    <citation>Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004 Aug 1;39(3):309-17. Epub 2004 Jul 15. Erratum in: Clin Infect Dis. 2004 Oct 1;39(7):1093. Clin Infect Dis. 2005 Apr 1;40(7):1077.</citation>
    <PMID>15306996</PMID>
  </reference>
  <reference>
    <citation>Vallés J, Palomar M, Alvárez-Lerma F, Rello J, Blanco A, Garnacho-Montero J, Martín-Loeches I; GTEI/SEMICYUC Working Group on Bacteremia. Evolution over a 15-year period of clinical characteristics and outcomes of critically ill patients with community-acquired bacteremia. Crit Care Med. 2013 Jan;41(1):76-83. doi: 10.1097/CCM.0b013e3182676698.</citation>
    <PMID>23222266</PMID>
  </reference>
  <reference>
    <citation>Herrmann JB, Muenstermann M, Strobel L, Schubert-Unkmeir A, Woodruff TM, Gray-Owen SD, Klos A, Johswich KO. Complement C5a Receptor 1 Exacerbates the Pathophysiology of N. meningitidis Sepsis and Is a Potential Target for Disease Treatment. mBio. 2018 Jan 23;9(1). pii: e01755-17. doi: 10.1128/mBio.01755-17.</citation>
    <PMID>29362231</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Escherichia coli Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

